BNT162b2 versus mRNA-1273 mRNA COVID-19 vaccines as the third booster for the patients with underlying cancer
Saved in:
Main Authors: | Amnuay Kleebayoon, Viroj Wiwanitkit |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-12-01
|
Series: | The Journal of Association of Chest Physicians |
Online Access: | https://journals.lww.com/10.4103/jacp.jacp_31_23 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01) -
Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01) -
Acute myocarditis after the third dose of COVID‐19 mRNA‐1273 vaccine
by: Takayuki Yamada
Published: (2023-05-01) -
Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
by: Lilia M. Sierra Galan, et al.
Published: (2025-01-01) -
Distinct response patterns of endothelial markers to the BNT162b2 mRNA COVID-19 booster vaccine are associated with the spike-specific IgG antibody production
by: Beatriz Castro-Robles, et al.
Published: (2025-01-01)